secwatch.observer — SEC 8-K summary
======================================

Issuer:     bioAffinity Technologies, Inc. (BIAF)
CIK:        0001712762
Form:       8-K
Filed at:   2023-05-15T23:59:59+00:00
Accession:  0001493152-23-017087
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

bioAffinity Q1 net loss $1.5M; cash $9.8M; names new CFO
--------------------------------------------------------

- Revenue of $1,000 from CyPath Lung royalties; no revenue in prior-year period.
- Net loss of $1.5M ($0.18 per share) unchanged YoY; SG&A rose to $1.2M from $395k.
- Cash and cash equivalents $9.8M at March 31, 2023; expects to fund operations for at least 12 months.
- Appointed Michael Dougherty as CFO, most recently CFO of Amazon's Alexa commercial domains.
- U.S. patent allowance for porphyrin cancer treatment compounds through OncoSelect Therapeutics.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1712762/000149315223017087/0001493152-23-017087-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1712762/000149315223017087/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-017087

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer